文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

异基因造血干细胞移植后移植物功能不良的临床特征、病理生理与治疗

Clinical features, pathophysiology, and therapy of poor graft function post-allogeneic stem cell transplantation.
PubMed 文献 · Blood Adv · 2022-01-01

该综述聚焦异基因造血干细胞移植后出现的移植物功能不良(PGF),其定义为供者嵌合率100%时仍存在多系血细胞减少。文章梳理了PGF的临床特征、相关危险因素(如巨细胞病毒再激活和移植物抗宿主病)、病理生理机制(涉及干细胞数量或功能、骨髓微环境缺陷及免疫抑制),并总结了改善干细胞数量与功能、微环境支持及免疫调节等治疗策略的现状与前景。

要点

  • PGF定义为供者嵌合率100%时出现多系血细胞减少,是alloSCT严重并发症。
  • 巨细胞病毒再激活和移植物抗宿主病等免疫相关因素与PGF发生相关。
  • 治疗策略包括改善干细胞数量与功能、微环境支持及新兴免疫调节,疗效不一。

核心结论

  • PGF是alloSCT后严重并发症,需综合评估干细胞、微环境及免疫因素以指导治疗。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • PGF以100%供者嵌合状态下多系血细胞减少为特征。
  • 巨细胞病毒再激活和移植物抗宿主病与PGF发生相关。
  • 病理生理涉及干细胞数量或生产力异常、骨髓微环境组分缺陷及免疫抑制。
  • 改善干细胞数量与功能及微环境支持的治疗疗效不一,免疫调节治疗使用有限但新兴疗法有前景。

临床怎么用

  • 临床管理PGF需从干细胞数量与功能、骨髓微环境及免疫抑制三方面评估并制定个体化策略。

局限性

  • 需更多临床研究确立PGF的其他危险因素并描述结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Poor graft function (PGF), defined by the presence of multilineage cytopenias in the presence of 100% donor chimerism, is a serious complication of allogeneic stem cell transplant (alloSCT). Inducers or potentiators of alloimmunity such as cytomegalovirus reactivation and graft-versus-host disease are associated with the development of PGF, however, more clinical studies are required to establish further risk factors and describe outcomes of PGF. The pathophysiology of PGF can be conceptualized as dysfunction related to the number or productivity of the stem cell compartment, defects in bone marrow microenvironment components such as mesenchymal stromal cells and endothelial cells, or immunological suppression of post-alloSCT hematopoiesis. Treatment strategies focused on improving stem cell number and function and microenvironment support of hematopoiesis have been attempted with variable success. There has been limited use of immune manipulation as a therapeutic strategy, but emerging therapies hold promise. This review details the current understanding of the causes of PGF and methods of treatment to provide a framework for clinicians managing this complex problem.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Prabahran A, Koldej R, Chee L, et al. Clinical features, pathophysiology, and therapy of poor graft function post-allogeneic stem cell transplantation. Blood Adv. 2022. PMID: 34492685. doi:10.1182/bloodadvances.2021004537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。